NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS
The main objectives and strategies for treatment of atrial fibrillation (AF), one of the most common cardiac arrhythmia, are seen. A combination of strategies for heart rate control in patients with atrial fibrillation receiving rhythm-controling therapy is preferred at present, according to current...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/993 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227802767785984 |
|---|---|
| author | S. Yu. Martsevich Yu. V. Lukina |
| author_facet | S. Yu. Martsevich Yu. V. Lukina |
| author_sort | S. Yu. Martsevich |
| collection | DOAJ |
| description | The main objectives and strategies for treatment of atrial fibrillation (AF), one of the most common cardiac arrhythmia, are seen. A combination of strategies for heart rate control in patients with atrial fibrillation receiving rhythm-controling therapy is preferred at present, according to current guidelines. Amiodarone, one of the most effective anti-arrhythmic drugs with an extensive evidence base, remains the drug of reserve because of serious side effects. A new drug, dronedarone, has electrophysiological properties attributable to all four classes of antiarrhythmic drugs. According to meta-analysis of randomized clinical trials dronedarone is inferior to amiodarone in prevention of AF recurrences, but it is superior to amiodaron in safety. However , in 2011 dronedarone was included in the Food and Drug Administration (FDA) list of drugs that require further analysis in connection with appearance of the new information about its safety. |
| format | Article |
| id | doaj-art-8569af08ac6e429bbcf4702a45e0a5dd |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-8569af08ac6e429bbcf4702a45e0a5dd2025-08-23T10:00:25ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-017677077410.20996/1819-6446-2011-7-6-770-774992NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONSS. Yu. Martsevich0Yu. V. Lukina1State Research Center for Preventive Medicine I.M. Setchenov First Moscow State Medical UniversityState Research Center for Preventive Medicine I.M. Setchenov First Moscow State Medical UniversityThe main objectives and strategies for treatment of atrial fibrillation (AF), one of the most common cardiac arrhythmia, are seen. A combination of strategies for heart rate control in patients with atrial fibrillation receiving rhythm-controling therapy is preferred at present, according to current guidelines. Amiodarone, one of the most effective anti-arrhythmic drugs with an extensive evidence base, remains the drug of reserve because of serious side effects. A new drug, dronedarone, has electrophysiological properties attributable to all four classes of antiarrhythmic drugs. According to meta-analysis of randomized clinical trials dronedarone is inferior to amiodarone in prevention of AF recurrences, but it is superior to amiodaron in safety. However , in 2011 dronedarone was included in the Food and Drug Administration (FDA) list of drugs that require further analysis in connection with appearance of the new information about its safety.https://www.rpcardio.online/jour/article/view/993atrial fibrillationantiarrhythmic drugsamiodaronedronedaronesafetyefficacyrandomized clinical trialsmeta-analysis |
| spellingShingle | S. Yu. Martsevich Yu. V. Lukina NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS Рациональная фармакотерапия в кардиологии atrial fibrillation antiarrhythmic drugs amiodarone dronedarone safety efficacy randomized clinical trials meta-analysis |
| title | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS |
| title_full | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS |
| title_fullStr | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS |
| title_full_unstemmed | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS |
| title_short | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS |
| title_sort | new antiarrhythmic drug for the treatment of atrial fibrillation study data clinical guidelines regulatory agency recommendations |
| topic | atrial fibrillation antiarrhythmic drugs amiodarone dronedarone safety efficacy randomized clinical trials meta-analysis |
| url | https://www.rpcardio.online/jour/article/view/993 |
| work_keys_str_mv | AT syumartsevich newantiarrhythmicdrugforthetreatmentofatrialfibrillationstudydataclinicalguidelinesregulatoryagencyrecommendations AT yuvlukina newantiarrhythmicdrugforthetreatmentofatrialfibrillationstudydataclinicalguidelinesregulatoryagencyrecommendations |